About The Study: In a clinical trial that included 8,920 participants, a noninvasive, multitarget stool RNA test (ColoSense) for colorectal cancer screening showed high sensitivity for colorectal neoplasia (colorectal cancer and advanced adenoma) with significant improvement in sensitivity relative to the fecal immunochemical test. Specificity for no lesions on colonoscopy was comparable to existing molecular diagnostic tests.
Authors: Erica K. Barnell, M.D., Ph.D., of the Washington University School of Medicine in St. Louis, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2023.22231)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American College of Gastroenterology 2023 Annual Scientific Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
Journal
JAMA